CELLIVITY is available to adults only. Supplement pages are general product information; peptide records are not a sales offer and are not for human use.
Age confirmation is a declaration, not identity verification. Restricted research access still requires separate professional eligibility checks.Privacy and legal notice ↗
This two-component concept pairs a no-DAC CJC-1295 material with ipamorelin, placing two growth-hormone signalling mechanisms in one vial. The combination requires separate identity and content measurements; total purity alone cannot show that both declared components are correct.
Research focus
Combined no-DAC CJC-1295 and ipamorelin signalling research.
Current evidence context
No robust controlled human evidence establishes the blend as a recovery or longevity intervention. Combining two labels also combines their endocrine, analytical and immunogenicity uncertainties.
Questions this record follows
Can both peptides be identified and quantified independently?
Does co-formulation change stability, aggregation or analytical recovery?
How does combined signalling differ from each material alone in controlled models?
04 — LAB RESULTS & DOCUMENTS
One product. One place. One evidence trail.
Exact CELLIVITY-batch review is pending. Reference files below describe their own declared samples.
Purity, identity, per-vial content and sterility are separate results.
Product
CJC-1295 No DAC + Ipamorelin
Record
CEL-P-CIP-001
Files received
1
DOCUMENT RECEIVED · REVIEW PENDING
CJC-1295 No DAC + Ipamorelin analytical report
Report image shows CJC-1295 No DAC at 5.68 mg and Ipamorelin at 6.06 mg; CJC-1295 DAC was not detected.
Request current availability for a lawful institutional, analytical or laboratory purpose. We confirm the exact presentation, price, batch and document state before any next step.
Exact presentation review
Jurisdiction and purpose check
Batch-document confirmation
No medical or human-use guidance
SELECTED PRODUCTCJC-1295 No DAC + IpamorelinCEL-P-CIP-001 · response after manual review
CJC-1295 No DAC + Ipamorelin: before you enquire
What exactly does the selected format mean?＋
The mg or IU value is the declared material content per vial; it is not the container volume. Your selected presentation and quantity are saved with your enquiry. The final price is confirmed in the response.
Which batch will be supplied?＋
The specific batch and its documents are confirmed in the response. Files shown here may be supplier reference samples; the current record does not yet contain a qualified CELLIVITY lot dossier.
When can it arrive in Thailand?＋
For confirmed local stock, the planned window is 2–3 working days in Thailand. Pattaya timing is agreed directly. Incoming or specially sourced products have a separate estimate, confirmed before a commitment.
Can I enquire about several products together?＋
Yes. Add each format and quantity to the cart, then send one availability enquiry. Your selected items are kept together for review.
CELLIVITY
CJC-1295 No DAC + Ipamorelin
CEL-P-CIP-001 · 5 mg + 5 mg
This two-component concept pairs a no-DAC CJC-1295 material with ipamorelin, placing two growth-hormone signalling mechanisms in one vial. The combination requires separate identity and content measurements; total purity alone cannot show that both declared components are correct.
Combined no-DAC CJC-1295 and ipamorelin signalling research.
Follow the sources
No robust controlled human evidence establishes the blend as a recovery or longevity intervention. Combining two labels also combines their endocrine, analytical and immunogenicity uncertainties.
Can both peptides be identified and quantified independently?
Does co-formulation change stability, aggregation or analytical recovery?
How does combined signalling differ from each material alone in controlled models?
Lab documents
CELLIVITY lot review pending
CJC-1295 No DAC + Ipamorelin analytical report · 26 Aug 2025 · CS-ci10825
Combination use adds endocrine and product-quality uncertainty; component evidence does not validate the blend.
